Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Ocular Therapeutix ( (OCUL) ).
On September 30, 2025, Ocular Therapeutix announced updates on its clinical trials for AXPAXLI, including ongoing Phase 3 trials for wet AMD and plans for trials in NPDR. The SOL-1 and SOL-R trials for wet AMD are progressing, with SOL-1 expected to yield results in early 2026 and SOL-R in 2027, potentially leading to a new drug application. Additionally, the company plans to initiate the SOL-X extension trial and HELIOS-2 and HELIOS-3 trials for NPDR, aiming to expand its market presence. A notice of allowance for a patent related to AXPAXLI was also received, potentially strengthening the company’s intellectual property portfolio.
The most recent analyst rating on (OCUL) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Ocular Therapeutix stock, see the OCUL Stock Forecast page.
Spark’s Take on OCUL Stock
According to Spark, TipRanks’ AI Analyst, OCUL is a Neutral.
Ocular Therapeutix’s stock score is primarily impacted by its financial challenges, including declining revenues and persistent losses. However, the technical analysis shows positive momentum, which is a favorable factor. The earnings call provided optimism with strategic advancements and a strong cash position, but the valuation remains unattractive due to negative profitability metrics. Overall, the stock presents a mixed outlook with significant financial risks but potential upside from clinical advancements.
To see Spark’s full report on OCUL stock, click here.
More about Ocular Therapeutix
Ocular Therapeutix, Inc. operates in the biotechnology industry, focusing on the development of innovative therapies for ocular diseases. The company’s primary product in development is AXPAXLI (OTX-TKI), a bioresorbable, intravitreal hydrogel incorporating axitinib, aimed at treating conditions such as wet age-related macular degeneration (AMD) and non-proliferative diabetic retinopathy (NPDR).
Average Trading Volume: 2,214,348
Technical Sentiment Signal: Buy
Current Market Cap: $2.18B
Find detailed analytics on OCUL stock on TipRanks’ Stock Analysis page.